79 results
DEFM14A
APGN
Apexigen Inc
30 Jun 23
Proxy related to merger
4:21pm
will be sought. There can be no assurance, however, that any additional approvals or actions will be obtained.
Accounting Treatment of the Merger (see … as well as the amount of cash that Apexigen will need to reserve for commitments and contingent liabilities.
There can be no assurance that the Merger
425
PYXS
Pyxis Oncology Inc
24 May 23
Business combination disclosure
7:05am
) reasonably designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements … reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and that receipts
8-K
EX-2.1
dk5g8dq9 xsvvt0f3
24 May 23
Pyxis Oncology to Acquire Apexigen
7:02am
8-K
jfyhov7
12 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:25pm
424B3
jb0wia
10 Apr 23
Prospectus supplement
4:03pm
424B3
0ww5 wg96e8
10 Apr 23
Prospectus supplement
4:02pm
POS AM
01w4 92j8
4 Apr 23
Prospectus update (post-effective amendment)
4:24pm
POS AM
cpwkpuq9 olkqjp165
4 Apr 23
Prospectus update (post-effective amendment)
4:23pm
8-K
EX-99.1
5fghj2 kug
14 Nov 22
Changes in Registrant's Certifying Accountant
4:07pm
424B3
q9ynay0kfthuqvh
9 Sep 22
Prospectus supplement
4:40pm
424B3
wo6krt4vcb1 zv
9 Sep 22
Prospectus supplement
4:38pm